



## ***Brendan C. McCarthy***

**PARTNER**

**San Diego**

P +1 858 436 8013

**Silicon Valley**

P +1 650 321 2400

Brendan is a partner in the San Diego office and is chair of the firm's Life Sciences Partnering practice.

Brendan specializes in structuring and negotiating strategic, complex “bet-the-company” collaborations, licenses, joint ventures and carve-out transactions on behalf of private and public companies in the biotechnology, pharmaceutical, medical device, agritech, and genomics industries. His experience also includes counseling clients in connection with pre-clinical and clinical research agreements, supply agreements, manufacturing agreements, and distribution agreements. In addition to representing company clients in their partnering and licensing activities, Brendan also represents a number of prominent venture capital funds and institutional investors in their financing activities and in their incubation and formation of life science companies.

Brendan has negotiated numerous licensing arrangements opposite major research institutions, particularly in situations where venture capital investors or entrepreneurs are licensing foundational intellectual property for a new biotechnology company. His

representative experience in this regard includes negotiating such agreements opposite the following research institutions (among various others): Broad Institute, CalTech, Cornell University, Dana-Farber Cancer Institute, Duke University, Fred Hutchinson Cancer Research Center, Harvard University, MD Anderson, MIT, Moffitt Cancer Center, Stanford University, University of California (various campuses), University of Cambridge, University of Oxford, University of Michigan, University of Texas (various campuses), University of Washington, and Yale University.

Prior to joining Gunderson Dettmer, Brendan was an attorney in the Palo Alto office of Cooley LLP.

Brendan holds a J.D. from the University of Chicago Law School as well as a B.S., with honors, in Computer Engineering from the University of Illinois at Urbana-Champaign. Brendan is a member of the State Bar of California.

## Representative Collaboration or Strategic Partnering Matters

- City Therapeutics, Inc. in its strategic collaboration with Bausch + Lomb to Develop a novel RNAi-based treatment for geographic atrophy, with a potential deal value of up to \$485 million plus royalties
- Vignette Bio, Inc. (a company incubated by Foresite Labs and backed by Foresite Capital) in its collaboration and license agreement with EpimAb Biotherapeutics to obtain ex-China rights to a BCMAXCD3 bispecific antibody, with a potential deal value of up to \$635 million plus royalties
- Xaira Therapeutics in its formation and various foundational strategic partnering and licensing transactions
- Contineum Therapeutics in its global license and development agreement with Janssen with potential deal value of over \$1 billion plus royalties
- Xencor in its global collaboration and license agreement with Janssen (with potential deal value of over \$1.2 billion plus royalties) to develop and commercialize novel B-cell targeted CD28 bispecific antibodies and to develop and commercialize Plamotamab, a CD20 x CD3 bispecific antibody
- Xencor in its global collaboration and license agreement with Janssen to develop and commercialize novel CD28 bispecific antibodies for the treatment of prostate cancer
- Xencor in its exclusive license agreement of three pre-clinical assets to Zenas Biopharma
- Xencor in its strategic collaboration with MD Anderson to develop and commercialize novel CD3 bispecific antibodies
- Xencor in its Global Development Agreement with Morphosys and Incyte
- Tscan Therapeutics in its collaboration and license agreement with Novartis to discover novel T cell receptor therapies for the treatment of solid tumors
- Tscan Therapeutics in its license agreement with Qiagen to develop T cell based laboratory test for COVID-19 immune response
- Tscan Therapeutics in its research collaboration and license agreement with Poseida to develop T cell receptor therapies for the treatment of COVID-19

- Kyverna Therapeutics in its collaboration and license agreement with Gilead to develop engineered T cell therapies for the treatment of autoimmune disease, with potential deal value of up to \$587.5 million plus royalties
- Tarsus Pharmaceuticals in various strategic partnering transactions, including its foundational in-license of TP-03 from Elanco and its development and license agreement with LianBio for the rights to TP-03 (XDEM VY) in China with potential deal value of \$200 million plus royalties
- Replicate Bioscience in its license and collaboration agreement with Precision NanoSystems to license lipid nano particle technology for use with self-replicating RNA
- Amgen in its exclusive license agreement with AmMax for AMG 820, a monoclonal antibody against CSF-1R
- Ultima Genomics in various strategic transactions since formation, including its development agreement with Regeneron for scaling genomic information for drug discovery and development and its supply agreement with Exact Sciences
- Foresite Capital in its formation of Alumis and related acquisition of a TYK2 inhibitor
- CG Oncology in its license and collaboration agreement granting Lepu Biotech exclusive rights to develop and commercialize cretostimogene and/or DDM in China
- Stemson Therapeutics in its in-license of a phase 2 cell therapy hair growth program from Aderans
- Synthetic Genomics in its collaboration and license agreement with Arcturus Therapeutics to develop self-amplifying RNA-based vaccines and therapeutics
- Synthetic Genomics in expanding its collaboration and license agreement with Lung Biotechnology (a subsidiary of United Therapeutics Corporation) to develop humanized pig organs
- Schrodinger in its multi-target research collaboration with Takeda
- Schrodinger in expanding its collaboration agreement with Nimbus Therapeutics

- Brightseed in various research, collaboration and license agreements, including with Archer Daniels Midland, Danone, Kallyope, ofi, and Pharmavite
- Molecule One in its strategic collaboration with CAS of the American Chemical Society to develop computer-aided synthesis design technologies
- Inari Medical in its license agreement with Inceptus Medical
- A royalty acquisition company in its secondary purchase of royalties from the licensor of an approved asset
- A royalty acquisition company in its secondary purchase of royalties for a late stage clinical asset
- A royalty acquisition company in its purchase of a royalty stream for an approved asset
- Synthetic Genomics in its strategic partnership with Archer Daniels Midland to commercialize Omega-3 DHA
- Synthetic Genomics in its strategic partnership with Exxon-Mobil to research and scale-up the production of biofuels from algae
- Sillajen in its immuno-oncology collaboration agreement with Regeneron for combination treatment in kidney cancer
- Crisi Medical Systems in its exclusive license and development agreement with Becton Dickinson

## Credentials

### EDUCATION

- University of Chicago Law School, J.D.
- University of Illinois at Urbana-Champaign, B.S., Computer Engineering with Honors

### BAR ADMISSIONS

- California

## Focus Areas

Life Sciences Licensing & Strategic Partnering  
Strategic Transactions & Licensing  
Life Sciences

### WEBINAR

## “What’s Market” in University Licenses in the Life Sciences Industry

Brendan presented the results of a quantitative analysis that aggregated and examined terms including royalty rates, milestones, sublicense income, equity grants and more across numerous license agreements and will discuss practical considerations for negotiating them.

## Related News & Insights

### CLIENT NEWS

City Therapeutics Enters Strategic Collaboration with Bausch + Lomb

### CLIENT NEWS

City Therapeutics Announces Launch with \$135M Series A Financing

### CLIENT NEWS

Foresite Labs Incubated Company Vignette Bio Enters License Agreement with EpimAb to Develop EMB-06

### CLIENT NEWS

AI Biotech Xaira Therapeutics Emerges from Stealth With \$1B in Funding

### EVENTS

Webinar: “What’s Market” in University Licenses in the Life Science Industry

### CLIENT NEWS

## Pipeline Therapeutics Enters into Global License and Development Agreement with Janssen

### CLIENT NEWS

## Replicate Bioscience Announces Collaboration with Precision NanoSystems to Deliver Up to 15 New srRNAs

### CLIENT NEWS

## Brightseed Announces Collaboration with Kallyope to Screen Plant-Based Bioactives

### CLIENT NEWS

## Brightseed Raises \$68M Series B Financing

### CLIENT NEWS

## Xencor Collaboration Agreement with Johnson & Johnson

### CLIENT NEWS

## Gunderson Dettmer Advises TScan Therapeutics on Initial Public Offering

### CLIENT NEWS

## Boingo Acquisition by Digital Colony

### CLIENT NEWS

## Tarsus Pharmaceuticals Strategic Partnership with LianBio